Press releases
-
-
Announced today the publication of the second edition of the Headway – A new roadmap in Brain Health: Focus Epilepsy Report
The report shows up to 40% of European patients living with epilepsy are receiving inadequate treatment to control seizures.
-
Angelini Pharma launches LIFE-GREENAPI as part of its green transition strategy
LIFE-GREENAPI will deploy a more efficient, greener, and innovative process for producing Active Pharmaceutical Ingredients (APIs), by switching from batch to flow chemistry technology.
-
-
EMA recommends extension of dalbavancin indication in children
Angelini Pharma announces that the European Commission (EC) has approved the extension of the indication of Xydalba® (dalbavancin) for the treatment of acute bacterial skin and soft tissue infections in children.
-
Angelini Industries appoints Jacopo Andreose new CEO of Angelini Pharma
Jacopo Andreose, who will take on the role from February 6, has over twenty years of experience in top management positions in the pharmaceutical industry.
-
New Headway Report
Ukraine–Russia conflict and climate change may lead to a new wave of mental health disorders in the coming months.
-
Giovanni Manarini new Chief Human Resources & Organization Officer
In his position, Manarini will report hierarchically to the CEO, Pierluigi Antonelli and will join the Leadership Team-the executive committee-of Angelini Pharma.
-
The European House – Ambrosetti and Angelini Pharma present Headway Epilepsy Report
The report highlights the need for closer European collaboration to tackle the burden of epilepsy
-
Angelini Pharma appoints Rafal Kaminski as new Chief Scientific Officer
Rafal Kaminski has broad international experience in drug discovery and innovation and will lead Angelini Pharma’s research and development (R&D) strategy. He will commence his role in January 2022.
